Product Description
Mechanisms of Action: Magainin-2 Analogue
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abeona
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Communicable Diseases|Diabetic Foot
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01590758 |
OneStep-1 | P3 |
Completed |
Diabetic Foot|Communicable Diseases |
2016-08-01 |
2019-03-19 |
Treatments |
|
NCT01594762 |
OneStep-2 | P3 |
Completed |
Communicable Diseases|Diabetic Foot |
2016-07-01 |
2019-03-19 |
Treatments |
|
NCT00563394 |
MSI-78-303 | P3 |
Completed |
Diabetic Foot |
1996-07-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00563433 |
MSI-78-304 | P3 |
Completed |
Diabetic Foot |
1996-07-01 |
2024-11-27 |
Primary Endpoints|Treatments |